| Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes has been analyzed in a multi-cancer bioinformatics approach. | None |
| Together, these results suggest a novel mechanism regulating PATZ1 expression based on the upregulation of miR-29b expression induced by Ras oncogene. | None |
| these contrasting signatures precisely match those proposed to confer bias toward Hras(CAA61CTA) versus Braf(GTG636GAG) mutations in the original tumor sets. Our findings highlight a novel mechanism whereby exposure history acts through strand-biased mutagenesis to specify activation of preferred oncogenes | None |
| ESR1 inhibits senescence-like phenotype and facilitates transformation induced by oncogenic ras in human mammary epithelial cells | None |
| we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated CIB1 expression. We previously described the Ca(2+)-myristoyl switch function of CIB1, and its ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1), a location where SK1 is known to elicit oncogenic signalling. | None |
| Studies indicate that RAS proteins were among the first oncogenes identified and are mutationally activated in 30% of all cancer types. | None |
| Studies on the promoter region of the c-Ha-ras oncogene. | None |
| Co-operation in cell transformation between BK virus and the human c-Harvey-ras oncogene. | None |
| Cooperation in oncogenesis between BK virus early region gene and the activated human c-Harvey ras oncogene. | None |
| Cotransfection of granulosa cells with simian virus 40 and Ha-RAS oncogene generates stable lines capable of induced steroidogenesis. | None |
| Different biological effects of c-myc and H-ras oncogene expression in EBV-infected human lymphoblasts. | None |
| Transformation of BALB/3T3 cells with EJ/T24/H-ras oncogene inhibits adenylate cyclase response to beta-adrenergic agonist while increases muscarinic receptor dependent hydrolysis of inositol lipids. | None |
| Detection of two TaqI polymorphisms in the VTR region of the human HRAS1 oncogene. | None |
| Mechanism of H-ras oncogene activation in mouse squamous carcinoma induced by an alkylating agent. | None |
| the oncogenic Hras mutation modulates energy homeostasis in vivo. | None |
| PRKD1-mediated classical protein secretory pathway regulates the H-Ras oncogene-induced senescence-associated secretory phenotype. | None |
| Tipifarnib effectively inhibits oncogenic HRAS-driven tumorigenesis and abrogating adaptive signaling improves responses. NF1 and GNAS mutations drive acquired resistance to Hras inhibition, supporting the on-target effects of the drug | None |
| Localization of the oncogene c-Ha-ras1 outside the aniridia-Wilms tumor-associated deletion of chromosome 11(del 11p13) using somatic cell hybrids. | None |
| The immediate-early enhancer element of herpes simplex virus type 1 can replace a regulatory region of the c-Ha-ras1 oncogene required for transformation. | None |
| Transformation of established murine fibroblasts with an activated cellular Harvey-ras oncogene or the polyoma virus middle T gene increases cell permissiveness to parvovirus minute-virus-of-mice. | None |